RSV Vaccination

RSV stands for respiratory syncytial virus, which is an important cause of a type of pneumonia.

It most often causes mild, cold-like symptoms, and infects up to 90% of children during the first 2 years of life, who often become a source of reinfection for older children and adults. However, babies under one year of age, and older adults, can suffer much more serious infection requiring hospitalisation.  Frail older adults with pre-existing medical conditions are most vulnerable to complications and death.

The risk of needing hospitalisation increases with age. No anti-viral medication is effective, so only supportive measures can be used for treatment. Accurate figures are not available because not all cases are fully investigated and reported, but there are estimated to be 1,200 deaths in people aged 45 to 74 years and 4,000 deaths in those aged over 75 years in England each winter.

Two new vaccines are now available to prevent infection; Arexvy and Abrysvo. Both are offered at the Fleet Street Clinic, please check for availability since there have been recent supply issues.

Either can be considered by older, frail adults, and people with a significant history of lung disease or previous severe chest infection.

Arexvy, made by GSK, is licensed for people aged over 60.

Abrysvo, made by Pfizer, is licensed for people aged over 60. Additionally, this vaccine is licensed and recommended during pregnancy, from 28 weeks onwards, to protect newborn infants via maternal antibodies.

The NHS has recently announced that it will be offering the RSV vaccine during pregnancy and to individuals aged 75 to 79 – please check your eligibility and for the latest NHS vaccination criteria, since this may be subject to change. The Fleet Street Clinic is not able to provide vaccinations free of charge via the NHS.